Main Article Content

Abstract

Arterial hypertension, a pervasive and multifactorial cardiovascular disorder, continues to
pose a significant global health challenge. This paper explores the intricate interplay between
chemical exposures and the onset of arterial hypertension, shedding light on the diverse mechanisms
through which various environmental and endogenous chemicals may contribute to the
development and exacerbation of this disease. Emphasizing the importance of understanding
chemical-induced vascular alterations, the review synthesizes current knowledge on the impact of
pollutants, heavy metals, pharmaceuticals, and endocrine-disrupting chemicals on blood pressure
regulation. Furthermore, it delves into the molecular pathways implicated in chemical-induced
vascular dysfunction, oxidative stress, inflammation, and endothelial dysfunction. A comprehensive
analysis of epidemiological studies and experimental models underscores the relevance of chemical
exposures as potential risk factors for arterial hypertension. Ultimately, this review provides
valuable insights into the complex relationship between chemical agents and the pathogenesis of
arterial hypertension, offering a foundation for future research and preventive strategies.

Keywords

Arterial hypertension cardiovascular disease chemical exposures environmental pollutants heavy metals pharmaceuticals endocrine-disrupting chemicals vascular dysfunction oxidative stress inflammation endothelial dysfunction blood pressure regulation epidemiology risk factors preventive strategies

Article Details

How to Cite
Nozimjon, S. S., & Makhmudovich, A. H. (2024). Chemical Effects on the Origin of Arterial Hypertension Disease. Central Asian Journal of Medical and Natural Science, 5(1), 567-572. https://doi.org/10.17605/cajmns.v5i1.2376

References

  1. M. C. Acelajado, Z. H. Hughes, S. Oparil, and D. A. Calhoun, “Treatment of resistant and refractory hypertension,” 2017.
  2. A. S. Al-Abrash, F. A. Al-Quobaili, and G. N. Al-Akhras, “Catalase evaluation in different human diseases associated with oxidative stress,” Saudi Med. J., vol. 21, pp. 826–830, 2000.
  3. J. Barnoya and S. A. Glantz, “Cardiovascular effects of secondhand smoke: nearly as large as smoking,” Circulation, vol. 111, pp. 2684–2698, 2005.
  4. J. Auer, R. Berent, E. Lassnig, and B. Eber, “C-reactive protein and coronary artery disease,” Jpn. Heart J., vol. 43, pp. 607–619, 2002.
  5. R. M. Palmer, A. G. Ferrige, and S. Moncada, “Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor”.
  6. R. W. Alexander, R. A. Hennigar, and K. K. Griendling, “Pathogenesis of hypertension: vascular mechanisms,” in Atlas of Heart Diseases: Atherosclerosis—Risk Factors & Treatment, E. Braunwald, Ed., Philadelphia, PA: Current Medicine, 1995, pp. 4.1--4.16.
  7. S. A. Atlas, “The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition,” J. Manag. Care & Spec. Pharm., vol. 13, pp. 9–20, 2007.
  8. C. C. Almenara et al., “Chronic cadmium treatment promotes oxidative stress and endothelial damage in isolated rat aorta,” 2014.
  9. H. A. Al-Naemi and S. C. Das, “Cadmium-induced endothelial dysfunction mediated by asymmetric dimethylarginine,” 2014.
  10. S. A. Ahmad et al., “Electrocardiographic abnormalities among arsenic-exposed persons through groundwater in Bangladesh,” J. Health. Popul. Nutr., vol. 24, pp. 221–227, 2006.
  11. Central Asian Journal of Medical and Natural Science 2024, 5, 567-572 https://cajmns.centralasianstudies.org/index.php/CAJMNS
  12. P. Muntner, “Measurement of blood pressure in humans: A scientific statement from the american heart association,” Hypertension, vol. 73, no. 5, 2019, doi: 10.1161/HYP.0000000000000087.
  13. S. Blankenberg et al., “Circulating cell adhesion molecules and death in patients with coronary artery disease,” Circulation, vol. 104, pp. 1336–1342, 2001.
  14. M. Bunderson, J. D. Coffin, and H. D. Beall, “Arsenic induces peroxynitrite generation and cyclooxygenase-2 protein expression in aortic endothelial cells: possible role in atherosclerosis,” Toxicol. Appl. Pharmacol., vol. 184, pp. 11–18, 2002.
  15. S. K. Wilson, “Role of oxygen-derived free radicals in acute angiotensin II-induced hypertensive vascular disease in the rat”.
  16. D. G. Harrison, “Physiological aspects of vascular endothelial cell interactions in hypertension and atherosclerosis,” 1996.
  17. X.-M. Zhang and E. F. Ellis, “Superoxide dismutase decreases mortality, blood pressure, and cerebral blood flow responses induced by acute hypertension in rats”.
  18. F. D. Fuchs, “High Blood Pressure and Cardiovascular Disease,” Hypertension, vol. 75, no. 2, pp. 285–292, 2020, doi: 10.1161/HYPERTENSIONAHA.119.14240.
  19. X. Cao, “COVID-19: immunopathology and its implications for therapy,” Nat. Rev. Immunol., vol. 20, no. 5, pp. 269–270, 2020, doi: 10.1038/s41577-020-0308-3.
  20. M. R. Mehra, “Cardiovascular disease, drug therapy, and mortality in COVID-19,” N. Engl. J. Med., vol. 382, no. 25, 2020, doi: 10.1056/NEJMoa2007621.
  21. N. Galiè, “Risk stratification and medical therapy of pulmonary arterial hypertension,” Eur. Respir. J., vol. 53, no. 1, 2019, doi: 10.1183/13993003.01889-2018.
  22. J. D. Williamson, “Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial,” JAMA - J. Am. Med. Assoc., vol. 321, no. 6, pp. 553–561, 2019, doi: 10.1001/jama.2018.21442.
  23. T. J. Guzik, “COVID-19 and the cardiovascular system: Implications for risk assessment, diagnosis, and treatment options,” Cardiovasc. Res., vol. 116, no. 10, pp. 1666–1687, 2020, doi: 10.1093/cvr/cvaa106.
  24. H. R. Reynolds, “Renin–angiotensin–aldosterone system inhibitors and risk of covid-19,” N. Engl. J. Med., vol. 382, no. 25, pp. 2441–2448, 2020, doi: 10.1056/NEJMoa2008975